A London-based company that is working on developing psychedelics as potential medicines officially has a Jersey City presence as Compass Pathways has planted their feet in a Downtown office space.
The biotechnology company recently celebrated the opening of its new U.S. office in Jersey City with a ribbon-cutting ceremony attended by company leaders, employees and local officials, including Jersey City Mayor James Solomon and U.S. House Representative Rob Menendez Jr. Situated at 30 Montgomery Street, the new 6,327-square-foot office will serve as a hub for Compass employees across the tri-state area.
The space opens as Compass advances U.S. commercial readiness activities for COMP360, its investigational synthetic psilocybin treatment program for depression. The company anticipates a potential U.S. launch in the first half of 2027, subject to FDA approval.
“Today is about more than an office – it is about the Compass colleagues who will fill this space with purpose and the people living with serious mental health conditions who are at the heart of our work,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “I’ve spent a significant part of my career in New Jersey, and I’ve seen firsthand the strength of the life sciences community here.”
Compass says they selected Jersey City because of its proximity to one of the country’s most established life sciences and healthcare ecosystems, access to a strong local talent pool, and its growing role as a destination for biotechnology innovation. The company currently has approximately 175 employees in the United States, with New Jersey representing one of Compass’ largest employee populations in the country.
Looking for your next opportunity in the area? Explore local openings on the Jersey Digs job board.
